Blocking mTOR Signalling with Rapamycin Ameliorates Imiquimod-induced Psoriasis in Mice

• Auteurs principaux: Claudia Bürger (Auteur), Nitesh Shirsath (Auteur), Victoria Lang (Auteur), Sandra Diehl (Auteur), Roland Kaufmann (Auteur), Andreas Weigert (Auteur), Ying-ying Han (Auteur), Christian Ringel (Auteur), Peter Wolf (Auteur)
• Format: Livre
• Publié: Medical Journals Sweden, 2017-06-01T00:00:00Z.
• Sujets: article
• Accès en ligne: Connect to this object online.

The mTOR (mechanistic target of rapamycin) inhibitor rapamycin has long been known for its immune suppressive properties, but it has shown limited therapeutic success when given systemically to patients with psoriasis. Recent data have shown that the mTOR pathway is hyperactivated in lesional psoria...